Analysts Set Surgery Partners, Inc. (NASDAQ:SGRY) Price Target at $36.56

Shares of Surgery Partners, Inc. (NASDAQ:SGRY) have received an average rating of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $36.75.

Several equities analysts have recently issued reports on SGRY shares. JPMorgan Chase & Co. lowered their price target on Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a research report on Tuesday, December 3rd. Macquarie reaffirmed an “outperform” rating and issued a $34.00 price target on shares of Surgery Partners in a research report on Tuesday, November 19th. Bank of America started coverage on Surgery Partners in a research report on Monday, December 16th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Royal Bank of Canada lowered their price target on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, November 20th.

Insiders Place Their Bets

In other news, insider Harrison R. Bane sold 56,315 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the completion of the sale, the insider now owns 107,037 shares of the company’s stock, valued at $2,744,428.68. This represents a 34.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO David T. Doherty sold 13,641 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $25.61, for a total transaction of $349,346.01. Following the sale, the chief financial officer now directly owns 108,862 shares of the company’s stock, valued at $2,787,955.82. The trade was a 11.14 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 96,733 shares of company stock valued at $2,480,106. 2.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Surgery Partners

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of Surgery Partners by 3.1% during the 3rd quarter. FMR LLC now owns 18,311,867 shares of the company’s stock valued at $590,375,000 after purchasing an additional 546,869 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Surgery Partners by 110.2% during the 4th quarter. Janus Henderson Group PLC now owns 11,554,845 shares of the company’s stock valued at $244,616,000 after purchasing an additional 6,057,477 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Surgery Partners by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 7,618,404 shares of the company’s stock valued at $161,282,000 after purchasing an additional 172,271 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Surgery Partners by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,577,861 shares of the company’s stock valued at $75,739,000 after purchasing an additional 563,812 shares during the last quarter. Finally, King Street Capital Management L.P. increased its position in shares of Surgery Partners by 93.1% during the 4th quarter. King Street Capital Management L.P. now owns 2,800,000 shares of the company’s stock valued at $59,276,000 after purchasing an additional 1,350,000 shares during the last quarter.

Surgery Partners Stock Performance

Shares of SGRY stock opened at $23.97 on Thursday. Surgery Partners has a 12 month low of $19.50 and a 12 month high of $33.97. The stock has a market cap of $3.05 billion, a PE ratio of -49.94, a price-to-earnings-growth ratio of 19.21 and a beta of 2.60. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. The company’s fifty day moving average price is $23.21 and its 200-day moving average price is $26.36.

Surgery Partners (NASDAQ:SGRY) last announced its earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The firm had revenue of $864.40 million for the quarter, compared to analysts’ expectations of $828.09 million. On average, equities analysts expect that Surgery Partners will post 0.67 EPS for the current fiscal year.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.